1. 1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC). (September 2015) Authors: Miles, D.; Cameron, D.; Bondarenko, I.; Lyudmila, M.; Alcedo, J.C.; Lopez, R.I.; Im, S.A.; Canon, J.L.; Shparyk, Y.; Yardley, D.; Masuda, N.; Ro, J.; Hubeaux, S.; Quah, C.; Bais, C.; O'Shaughnessy, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bovine besnoitiosis (Besnoitia besnoiti) in an Irish dairy herd. (11th June 2016) Authors: Ryan, E. G.; Lee, A.; Carty, C.; O'Shaughnessy, J.; Kelly, P.; Cassidy, J. P.; Sheehan, M.; Johnson, A.; de Waal, T. Journal: Veterinary record Issue: Volume 178:Number 24(2016) Page Start: 608 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Detection of anthelmintic resistance on two Irish beef research farms. (2nd August 2014) Authors: O'Shaughnessy, J.; Earley, B.; Mee, J. F.; Doherty, M. L.; Crosson, P.; Barrett, D.; Prendiville, R.; Macrelli, M.; de Waal, T. Journal: Veterinary record Issue: Volume 175:Number 5(2014) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Facial Expression Overrides Lumbopelvic Kinematics for Clinical Judgements about Low Back Pain Intensity. (29th March 2016) Authors: Courbalay, A.; Deroche, T.; Descarreaux, M.; Prigent, E.; O'Shaughnessy, J.; Amorim, M.-A. Journal: Pain research and management Issue: Volume 2016(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer. Issue 2 (February 2019) Authors: Golshan, M.; Wong, S.; Loibl, S.; Huober, J.B.; O'Shaughnessy, J.; Rugo, H.S.; Wolmark, N.; McKee, M.D.; Maag, D.; Sullivan, D.M.; Metzger-Filho, O.; Von Minckwitz, G.; Geyer, C.E.; Sikov, W.M.; Untch, M. Journal: European journal of surgical oncology Issue: Volume 45:Issue 2(2019) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2. (November 2022) Authors: Jhaveri, K.; O'Shaughnessy, J.; Fasching, P.; Cardoso, F.; Tolaney, S.; Hamilton, E.; Sharma, V.K.; Biswas, C.; Haftchenary, S.; Pathak, P.; Rugo, H. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. One-year parasitological screening of stray dogs and cats in County Dublin, Ireland. Issue 6 (18th December 2018) Authors: Garcia-Campos, A.; Power, C.; O'Shaughnessy, J.; Browne, C.; Lawlor, A.; McCarthy, G.; O'Neill, E. J.; de Waal, T. Journal: Parasitology Issue: Volume 146:Issue 6(2019) Page Start: 746 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. (February 2018) Authors: Strasser-Weippl, K.; Sudan, G.; Ramjeesingh, R.; Shepherd, L.E.; O'Shaughnessy, J.; Parulekar, W.R.; Liedke, P.E.R.; Chen, B.E.; Goss, P.E. Journal: European journal of cancer Issue: Volume 90(2018) Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes. (April 2023) Authors: Johnston, S.; Toi, M.; O'Shaughnessy, J.; Rastogi, P.; Campone, M.; Neven, P.; Huang, C.S.; Huober, J.; Jaliffe, G. Garnica; Cicin, I.; Tolaney, S.; Goetz, M.P.; Rugo, H.; Senkus, E.; Testa, L.; Del Mastro, L.; Shimizu, C.; Wei, R.; Shahir, A.; Munoz, M. Journal: Breast Issue: Volume 68(2023) Page Start: S22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. (April 2023) Authors: Kümmel, S.; Schmid, P.; Harbeck, N.; Takahashi, M.; Untch, M.; Boileau, J.-F.; Cortes, J.; McArthur, H.; Dent, R.; O'Shaughnessy, J.; Pusztai, L.; Foukakis, T.; Park, Y.H.; Hui, R.; Cardoso, F.; Denkert, C.; Zhu, Y.; Pan, W.; Karantza, V.; Fasching, P. Journal: Breast Issue: Volume 68(2023)Supplement Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗